To overcome these limitations, we performed a prespecified analysis of the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) that compared the PCSK9 inhibitor alirocumab with placebo in patients with recent acute coronary syndrome (ACS).9 We used propensity score matching to compare patients in 3 strata of achieved LDL-C with alirocumab to patients in the placebo group with similar baseline characteristics and study medication adherence. This evidence concerns the gene PCSK9 and acute coronary syndrome.